MYCN-targeting vaccines and immunotherapeutics. Issue 9 (1st September 2016)

• Record Type: Journal Article
• Authors: Schramm, Alexander; Lode, Holger
• Is Part Of: Human vaccines & immunotherapeutics. Volume 12:Issue 9(2016)
• Page Start: 2257
• Page End: 2258
• Publication Date: 2016-09-01
• Subjects: DNA vaccination -- minigene -- MYCN -- neuroblastoma; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2016.1171430
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, 1 which is beneficial for approaches combatting tumor-specific MYCN. However, MYCN is a transcription factors that was considered a poor drug target, until recent approaches suggested that down-regulation of MYCN could be possible by indirect targeting using Aurora kinase inhibitors or BET inhibitors. These concepts were proven using preclinical models 2–6 and are now entering clinical trials.